You are viewing a free version of BCIQ, BioCentury's advanced business intelligence database for the biopharma industry.
Find partnering and investment opportunities, uncover and track competitive threats, dive into a company's financing and deal history, its pipeline and molecular targets of interest, and much more. Enter a Company name above to access free BCIQ profiles. Request a trial to unlock the full value of BCIQ.
University of Manitoba
Headquarters:Winnipeg, Canada
Year Founded:1877
Status:Academic
Biopharma related deals can be found by searching the organization's name in the BCIQ Deals Module*.*desktop version only

BioCentury | Feb 11, 2010

Distillery Therapeutics

Indication: Neurology

...Contact: Michael G. Fehlings, University Health Network, Toronto, Ontario, Canada e-mail: michael.fehlings@uhn.on.ca Contact: Soheila Karimi-Abdolrezaee, University of Manitoba...

BioCentury | Jun 04, 2020

Product Development

WHO restarts hydroxychloroquine testing as drug fails another COVID-19 trial

...researchers from the University of Minnesota, McGill University, the University of Alberta and the University of Manitoba...

BioCentury | Feb 16, 2017

Translation in Brief

WinSanTor, with feeling

...of California San Diego and Fernyhough is a professor of pharmacology and therapeutics at the University of Manitoba...

BioCentury | Jan 27, 2017

Company News

UCSD, U of Manitoba, St. Boniface Hospital Albrechtsen Research Center, WinSanTor deal

...Albrechtsen Research Center , Winnipeg, Manitoba University of California San Diego , La Jolla, Calif. University of Manitoba...
...San Diego, Calif. Business: Neurology Alicia Parker University of California San Diego WinSanTor Inc. St. Boniface Hospital Albrechtsen Research Center University of Manitoba...

BioCentury | Mar 31, 2016

Product R&D

Stalking Ebola

...could enter the clinic before year end. And this month, a third group from the University of Manitoba...
...NIH), Bethesda, Md. Public Health Agency of Canada (PHAC), Ottawa, Ontario Tsinghua University, Beijing, China University of Manitoba...

BioCentury | Jan 14, 2016

Distillery Therapeutics

Therapeutics: Leishmania glycosomal phosphoenolpyruvate carboxykinase (PEPCK)

...Z. et al. Sci. Transl. Med.; published online Oct. 21, 2015 doi:10.1126/scitranslmed.aac5477 CONTACT: Jude Uzonna, University of Manitoba...

BioCentury | Jan 07, 2016

Distillery Therapeutics

Therapeutics: Transient receptor potential cation channel subfamily M member 2 (TRPM2)

...Ontario e-mail: mprado@robarts.ca CONTACT: Vania Prado, same affiliation as above e-mail: vprado@robarts.ca CONTACT: Michael Jackson, University of Manitoba...

BioCentury | Jan 15, 2015

Distillery Therapeutics

Therapeutics: BCL2/adenovirus E1B 19kDa interacting protein 3 (BNIP3)

...Proc. Natl. Acad. Sci. USA; published online Dec. 8, 2014 doi:10.1073/pnas.1414665111 CONTACT: Lorrie A. Kirshenbaum, University of Manitoba...

BioCentury | Sep 25, 2014

Cover Story

Interrupting Ebola

...different mAbs that Mapp, Defyrus Inc. , the Public Health Agency of Canada and the University of Manitoba...
...ZMAb antibody mix provided by a team from the Public Health Agency of Canada and University of Manitoba...
...the Public Health Agency of Canada team, an associate professor of medical microbiology at the University of Manitoba...

BioCentury | Aug 30, 2014

Clinical News

ZMapp reverses advanced Ebola in monkeys

...reversed 100% of advanced Ebola cases. A research group led by Gary Kobinger of the University of Manitoba...

BioCentury | Dec 19, 2013

Distillery Therapeutics

Indication: Neurology

...Y. et al. PLoS Genet.; published online Oct. 31, 2013; doi:10.1371/journal.pgen.1003895 Contact: Geoffrey G. Hicks, University of Manitoba...

BioCentury | Jul 26, 2012

Targets & Mechanisms

Target on Ebola

...National Microbiology Laboratory at PHAC and adjunct professor of medical microbiology and immunology at the University of Manitoba...
...Public Health Agency of Canada , Winnipeg, Manitoba, Canada Sarepta Therapeutics Inc. (NASDAQ:SRPT), Bothell, Wash. University of Manitoba...
...al. Sci. Transl. Med. ; published online June 13, 2012; doi:10.1126/scitranslmed.3003876 Contact: Gary P. Kobinger, University of Manitoba...

BioCentury | Jun 21, 2012

Distillery Therapeutics

Indication: Infectious disease

...et al. Sci. Transl. Med.; published online June 13, 2012; doi:10.1126/scitranslmed.3003876 Contact: Gary P. Kobinger, University of Manitoba...

BioCentury | Feb 13, 2012

Emerging Company Profile

Halo: Treating DMD symptoms

...compound also improved cardiac and respiratory function, and reduced damage and improved recovery from exercise. University of Manitoba...
...Newton, Mass. Nash Avery Foundation , Minneapolis, Minn. Shire plc (LSE:SHP; NASDAQ:SHPGY), Dublin, Ireland University of Manitoba...

BioCentury | Sep 19, 2011

Clinical News

Bisphosphonates cancer data

...Pharma Ltd. (Tokyo, Japan) co-markets Fosamax with Merck's Banyu Pharmaceutical Co. Ltd. subsidiary in Japan. University of Manitoba...

BioCentury | Apr 29, 2010

Distillery Therapeutics

Indication: Infectious disease

...S. et al. J. Med. Chem.; published online April 7, 2010; doi:10.1021/jm1000437 Contact: Frank Schweizer, University of Manitoba...

BioCentury | Aug 03, 2018

Targets & Mechanisms

Oxitope’s oxidation play

...Tsimikas teamed up with Amir Ravandi, an assistant professor of cardiology and physiology at the University of Manitoba...
...Arkansas for Medical Sciences, Little Rock, Ark. University of California San Diego, La Jolla, Calif. University of Manitoba...

BioCentury | Apr 16, 2009

Targets & Mechanisms

NO: more muscles

...Researchers at the University of Manitoba and the Carolinas Medical Center have uncovered myogenesis-promoting properties in an over-the-counter...
...Carolinas Medical Center . Burczynski is a professor in the faculty of pharmacy at the University of Manitoba...
...Cambridge, Mass. Ikaria Holdings Inc. , Clinton, N.J. PTC Therapeutics Inc. , South Plainfield, N.J. University of Manitoba...

BioCentury | Apr 02, 2009

Distillery Therapeutics

Indication: Musculoskeletal disease

...under normal and diseased states; available for licensing from patent inventors Contact: Judy E. Anderson, University of Manitoba...
...G. et al. Mol. Pharm.; published online March 24, 2009; doi:10.1021/mp800226z Contact: Judy E. Anderson, University of Manitoba...

BioCentury | Oct 23, 2008

Cover Story

Suppressing the Suppressors

...advanced glycosylation end product-specific receptor (AGER; RAGE). Indeed, Saeid Ghavami, professor of physiology at the University of Manitoba...
...S100A8/A9 on several types of cancer cells," said Marek Los, former faculty member at the University of Manitoba...
...New York, N.Y. Merck KGaA (Xetra:MRK), Darmstadt, Germany Tokyo Women's Medical University , Tokyo, Japan University of Manitoba...

BioCentury | Jul 14, 2007

Clinical News

GABAergic system is possible asthma target

...Researchers from Sunnybrook Health Sciences Centre, University of Manitoba, and colleagues reported in Nature Medicine that a previously...

BioCentury | Feb 05, 2007

Finance

Ebb & Flow

...compound for apparently the wrong reasons. BMY returned its rights to CancerCare Manitoba and the University of Manitoba...

BioCentury | Feb 07, 2005

Company News

Medicure, University of Manitoba, University of Ottawa deal

...that reduce cholesterol and triglycerides through an undisclosed mechanism. Medicure Inc. (TSE:MPH; MCU), Winnipeg, Manitoba University of Manitoba...

BioCentury | Feb 02, 2004

Product Development

Plucked from the discard pile

...TSE:YM; LSE:YMBA, Mississauga, Ontario), then York Medical Inc., licensed tesmilifene from CancerCare Manitoba and the University of Manitoba...

BioCentury | Apr 14, 2003

Company News

Miraculins scientific advisory board update

...department of physics at the University of Manitoba; and Werner Ens, a professor of physics at the University of Manitoba WIR...

BioCentury | Sep 23, 2002

Company News

Arc Pharma board of directors update

...Inc. ; and Jerry Gray, dean of the I.H. Asper School of Business at the University of Manitoba WIR...

BioCentury | Feb 20, 2001

Clinical News

YM Biosciences starts Phase II with Tesmilifene

...U.S. and Canada. YM licensed Tesmilifine, a chemopotentiator, from CancerCare Manitoba (Winnipeg, Manitoba) and the University of Manitoba...

BioCentury | Nov 20, 2000

Tools & Techniques

Breathing life into BMY's reject

...see if it has better instincts than Bristol-Meyers Squibb Corp. York has acquired from the University of Manitoba...

BioCentury | Nov 20, 2000

Company News

York Medical Inc., CancerCare Manitoba, University of Manitoba deal

...to complete in 2001. York Medical Inc. , Mississauga, Ontario CancerCare Manitoba , Winnipeg, Manitoba University of Manitoba...

BioCentury | Nov 14, 2000

Company News

York Medical expands oncology pipeline

...licensed Tesmilifene, a small molecule intracellular histamine antagonist that functions as a chemopotentiator, from the University of Manitoba...

BioCentury | Sep 25, 2000

Clinical News

Fibrostat topical transglutaminase inhibitor cream regulatory update

...The University of Manitoba (Winnipeg, Manitoba) received a Canadian patent covering the use of transglutaminase inhibitors to treat...

BioCentury | Sep 18, 2000

Clinical News

Cardoxal: Began Phase I trial

...pharmacokinetics trial of Cardoxal in 36 healthy volunteers. MPH licensed the small molecule from the University of Manitoba...

BioCentury | Mar 21, 1994

Company News

Avigen deal

...plans to develop gene therapies for prostate cancer. Avigen Avigen received a license from the University of Manitoba...